


Supplemental table A: The baseline characteristics of randomized controlled trials

study	No. of included patients	novel agent	Comparison	Trial identification number	
TM Beer 2014	1717	Enzalutamide	placebo	NCT01212991	phase 3
TM Beer 2017	602	Ipilimumab	placebo	NCT01057810	phase 3
CJ Ryan 2015	1088	Abiraterone	placebo	NCT00887198	phase 3
DF Penson 2016	396	Enzalutamide	Bicalutamide	STRIVE	phase 2
F Saad 2015	1560	Orteronel	placebo	NCT01193244	phase 3
DP Petrylak 2015	1059	Docetaxel+Lenalidomide	Docetaxel+placebo	NCT00988208	phase 3
WK Kelly 2012	1050	Docetaxel+Bevacizumab	Docetaxel+placebo	CALGB 90401	phase 3
R Pili 2011	210	Tasquinimod	placebo	NA	Phase 2
C Sternberg 2016	1245	Tasquinimod	placebo	NCT01234311	phase 3
JC Araujo 2013	1522	Docetaxel+Dasatinib	Docetaxel+placebo	NCT00744497	phase 3
ND. Shore 2016	375	Enzalutamide	Bicalutamide	NCT01288911	phase 2
H Akaza 2009	203	Bicalutamide	placebo	NA	phase 3
K Fizazi 2017	1199	Abiraterone	placebo	NCT01715285	phase 3
MP Wirth 2004	8113	Bicalutamide	placebo	NA	phase 3
JB Nelson 2012	594	Zibotentan	placebo	NCT00554229	phase 3
K Miller 2013	2577	Zibotentan	placebo	NCT00626548	phase 3
K Fizazi 2013	1,052	Docetaxel+Zibotentan	Docetaxel+placebo	NCT00617669	phase 3
ND James 2010	312	Zibotentan	placebo	NCT00090363	phase 2
DI Quinn 2013	1038	Docetaxel+Atrasentan	Docetaxel+placebo	NCT00134056	phase 3
MA Carducci 2007	809	Atrasentan	placebo	NA	phase 3
JB Nelson 2008	941	Atrasentan	placebo	NA	phase 3
KN Chi 2017	1022	Docetaxel+Custirsen	Docetaxel+placebo	NCT01188187	phase 3
IF Tannock 2013	1224	Docetaxel+Aflibercept	Docetaxel+placebo	NCT00519285	phase 3


NA=not available.

Supplements. Fig A.1 The flow diagram of the search process




Supplementary material Figure – Flow diagram showing the number of studies included in and excluded from the meta-analysis.


Supplements. Fig A.2 Risk of bias in all trials.




Supplements. Fig A.3 The convergent and lever graph in OS analysis.



Supplements. Fig A.4 Network meta-analysis of OS(A)/PFS(B) in all new agents in combination with docetaxel compared with placebo and docetaxel.



Supplements. Fig A.5 Subgroup of network meta-analysis.



Supplements. Fig A.6 The convergent and lever graph in PFS analysis.

